Cipla Q3 preview: Up to 7% YoY uptick seen in revenue. Margins to fall on a YoY and sequential basis
Cipla is expected to report a 3.1-7% year-on-year growth in its December quarter revenue, driven by demand for certain drugs, according to estimates by four brokerages. The topline range for Q3FY25 is projected to be between Rs 6,807 crore and Rs 7,070 crore.
The company’s profit after tax (PAT) for the reporting quarter is expected to be in the range of Rs 1,170 crore to Rs 1,217 crore. Among the four brokerages, Axis Securities remains the most bullish on Cipla’s PAT figures, estimating a 14% YoY growth, while Nuvama Institutional Equities is the most conservative, expecting a 2.2% decline.
The other brokerages whose estimates have been considered include Centrum Broking and PhillipCapital. The revenue estimates are highest for PhillipCapital, while Nuvama has the lowest estimates.
The street will closely watch updates on drugs like Abraxane and Lanreotide, as well as the launch timelines for others.
Cipla’s margins could face pressure both sequentially and YoY.
Stock Trading
Maximise Returns by Investing in the Right Companies
By — The Economic Times, Get Certified By India's Top Business News Brand
Stock Trading
Market 104: Options Trading: Kickstart Your F&O Adventure
By — Saketh R, Founder- QuickAlpha, Full Time Options Trader
Stock Trading
Technical Analysis for Everyone — Technical Analysis Course
By — Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities
Stock Trading
Stock Markets Made Easy
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Renko Chart Patterns Made Easy
By —
